#16
|
|||
|
|||
Íó ïðàâäà? ×åì øàìïàíèäû õóæå îçîíèäîâ?
|
#17
|
|||
|
|||
Öèòàòà:
íà âîïðîñû, êîòîðûå ÿ Âàì çäåñü çàäàë (ñîîáùåíèå ¹ 9)? ×åì, ê ïðèìåðó, Âàøå âîçìóùåíèå äî ãëóáèíû äóøè, î âåùàõ, êîòîðûå Âû íå çíàåòå, à Âàì òàê êàæåòñÿ, îòëè÷àåòñÿ îò ãëóáî÷àéøåãî âîçìóùåíèÿ ñîâåòñêèõ ãðàæäàí, ýêñïëóàòàöèåé ðàáî÷åãî êëàññà ïðè çàãíèâàþùåì êàïèòàëèçìå ? |
#18
|
|||
|
|||
Öèòàòà:
Çàòåì ïåðåéäåì ê îçîíèäàì. |
#19
|
|||
|
|||
Öèòàòà:
À ïî÷åìó Âû âîçìóòèëèñü ïî ïîâîäó ñðàâíåíèÿ âàøåãî äåòèùà ñ øàìïàíîòåðàïèåé? Âû ÷òî ñòàëêèâàëèëàñü ñ íåé? Âû èìååòå î íåé ïðåäñòàâëåíèå? Êàê Âû ìîæåòå ðàññóæäàòü äàæå íå ïîïðîáîâàâ? Èëè Âû çà? Èç-çà ïàòðèîòè÷åñêèõ ÷óâñòâ!!!! |
#20
|
||||
|
||||
Öèòàòà:
2)íå ðåêîìåíäóåòñÿ ê èñïîëüçîâàíèþ â îôèöèàëüíîé ìåäèöèíå â ÑØÀ, Êàíàäå, ßïîíèè, Ôðàíöèè è ò.ä è ò.ï. Îá ýòîì ëåãêî óçíàòü ëþáîìó ÷åëîâåêó, ïîçâîíèâ èëè íàïèñàâ ïèñüìî â ÀÌÀ (American Medical Association) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 3)òåîðåòè÷åñêàÿ áàçà ñêóäíàÿ, èññëåäîâàíèé ïî áåçîïàñíîñòè è ýôôåêòèâíîñòè êðàéíå ìàëî. Îá ýòîì ìîæíî óçíàòü, ñäåëàâ çàïðîñ â ÌåäËàéí [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] èëè Ñochrane [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
Öèòàòà:
|
#21
|
|||
|
|||
Óâàæàåìûé Åâãåíèé Åâãåíüåâè÷!
Ãäå ÿ âîçìóòèëñÿ? Çà÷åì Âû ïðèâåëè öèòàòó, êîòîðàÿ îòíîñèòñÿ ñîâñåì ê äðóãîìó òåêñòó. Òåì áîëåå ðå÷ü òàì èäåò íå î ìîåì âîçìóùåíèè äî ãëóáèíû äóøè, à Âàëåíòèí Àëåêñàíäðîâè÷à. Ïðîñòèòå, íî ó Âàñ óæå íå ïåðâûé ðàç ãàëëþöèíàöèè. ß ëèøü ïîïðîñèë Âàñ, êàê ñïåöèàëèñòà ïî øàìïàíèäàì, ñðàâíèòü, âíà÷àëå, èõ ñ ôòîðõèíîëîíàìè. |
#22
|
|||
|
|||
Öèòàòà:
Âû æå ó íàñ "íó î÷åíü ãðàìîòíûé áèîõèìèê" - âîò Âû è ñðàâíèâàéòå. |
|
#23
|
|||||
|
|||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Îáî âñåõ "óñïåõàõ" ÎÒ, çàñëóæèâàþùèõ âíèìàíèÿ, èìåþòñÿ ëèøü åäèíè÷íûå ñîîáùåíèÿ î÷åíü óçêîé ãðóïïû àâòîðîâ èç îïðåäåëåííûõ ñòðàí. Ýòî âîâñå íå åñòü çàêîíîìåðíîñòü, êàê Âû ïîíèìàåòå.  ëó÷øåì ñëó÷àå íàõîäêè, òðåáóþùèå ïîäòâåðæäåíèé. Îá ýòîì, êñòàòè, ïðèëè÷íûå àâòîðû è ðåçþìèðóþò. Îíè, â îòëè÷èå îò Âàñ, íå ïîçèöèîíèðóþò ÎÒ êàê ïàíàöåþ. Îíè íå ïóáëèêóþò "ïîêàçàíèÿ" ê ÎÒ äëÿ ëå÷åíèÿ âñåõ áîëåçíåé. Èì õâàòàåò è óìà è ñîâåñòè íå íàçûâàòü â ëó÷øåì ñëó÷àå ýêñïåðèìåíòàëüíûé ìåòîä ðåàëüíî ñóùåñòâóþùèì. Âû êñòàòè ðàíüøå î÷åíü ÷àñòî ïðèâîäèëè Ãåðìàíèþ â êà÷åñòâå îàçèñà ÎÒ. Òåïåðü, êîãäà íåêîòîðûå ó÷àñòíèêè ôîðóìà, âêëþ÷àÿ óáåäèâøåãîñÿ â ýòîì ñàìîëè÷íî Âàøåãî ïîêîðíîãî ñëóãó, ñîîáùèëè, ÷òî îçîíîì â Ãåðìàíèè â ïðèëè÷íîì îáùåñòâå íå ïàõíåò, ÷åãî òî ïîóìîëêëè. Óâåðåí, ÷òî è â Èçðàèëå, è â Èòàëèè ýòîò ìåòîä íèêîãî âñðüåç íå èíòåðåñóåò. Äóìàþ, ÷òî ó÷àñòíèêè ôîðóìà èç Èçðàèëÿ ýòî ïîäòâåðäÿò. Öèòàòà:
È ïîñëåäíåå, óâàæàåìûé Âëàäèìèð ßêîâëåâè÷. ß ïðåäëàãàë Âàì ñâîþ êàíäèäàòóðó â êà÷åñòâå îðãàíèçàòîðà è èñïîëíèòåëÿ êëèíèñïûòàíèé ìàñëà Îçîíèä íà áàçå êëèíèêè Àíäðîñ (åñëè ïîìíèòå ìû â ìåñÿö ïðèíèìàåì îêîëî 600 óðîëîãè÷åñêèõ è ãèíåêîëîãè÷åñêèõ áîëüíûõ). Òàê âîò, ÿ òàê è íå óñëûøàë íèêàêîãî âðàçóìèòåëüíîãî îòâåòà íà 2 ïðîñòûõ âîïðîñà: 1. Ïðåäïîëàãàåìàÿ íîçîëîãèÿ. ïðèêîòîðîé íàäî îöåíèòü ýôôåêòèâíîñòü îçîíèäà. 2. Êàêîâ áóäåò äèçàéí èññëåäîâàíèÿ. ß ðèñêíó ñêàçàòü, ÷òî íàâåðíîå çíàþ äàæå ïî÷åìó ÿ íå óñëûøàë îòâåòîâ íà ýòè âîïðîñû. Âû ïðèâûêëè èñïûòûâàòü îçîí âî âñåõ èïîñòàñÿõ â "äèçàéíå" - "íà äîêòîð ïîïðîáóé è íàïèøè çàêëþ÷åíèå". Èíà÷å âàøå ïðåäëîæåíèå íîñèëî áû áîëåå îôîðìëåííûé õàðàêòåð. Òóò êàê òî ïðåäñòàâèòåëè ðîññéñêîé êîìïàíèè "Íèæôàðì" ïîñåòèëè îäíîãî ìîåãî êîëëåãó-ãèíåêîëîãà ñ ïðåäëîæåíèåì ïîïðîáîâàòü êàêèå òî òàì î÷åðåäíûå âëàãàëèùíûå ñâå÷êè. Íà âîïðîñ î äèçàéíå èññëåäîâàíèÿ ñíà÷àëà õîòåëè áûëî ñêàçàòü "íà äîêòîð ïîïðîáóé, ïîòîì íàïèøè çàêëþ÷åíèå". Íî äîêòîð îêàçàëñÿ ïîñëîæíåå ñðåäíåãî è ñïðîñèë ïðî äèçàéí èññëåäîâàíèÿ. Òå åìó ÷åðåç ïàðó äíåé ïðèïåðëè "äèçàéí" íå äàëåêî óøåäøèé îò èõ ïåðâîãî ïðåäëîæåíèÿ. Ïîòîì ñêàçàëè äîêòîðó - òû òèïà ñàì áû äèçàéí òî ïðèäóìàë äëÿ íàñ . à ïîòîì áû è ñàì èñïûòàë. È, ãëàâíîå, ýòî - çàêëþ÷åíèå òî íå çàáóäü, ÿñåí ïåíü êàêîå. Èç îáùåíèÿ ñ ýòîé ïóáëèêîé ñòàëî ïîíÿòíî, ÷òî âî âñåì "Íèæôàðìå" ëþäåé. êîòîðûå ïîíèìàþò ÷òî òàêîå êëèíè÷åñêèå èñïûòàíèÿ ïðîñòî íåòó! À çà÷åì îíè, åñëè Ìèíçäðàâ è òàê âñå ïîäðÿä è îò âñåãî ðåãèñòðèðóåò. Òàê âîò, Âëàäìèð ßêîâëåâè÷, ÿ ðèñêíó ïðåäïîëîæèòü, ÷òî ðàäóæíîñòü áóäóùåãî ÎÒ, êàê è ñâå÷åê îò "Íèæôàðìà" (âìåñòå ñ ñàìèìè íèæôàðàìàìè è ìåäîçîíàèì) ïðÿìî ïðîïîðöèîíàëüíî ñòåïåíè âõîæäåíèÿ íàøåé ñòðàíû â öèâèëèçàöèþ. ×åì áîëüøå ýòîé ñàìîé öèâèëèçàöèè ó íàñ áóäåò. òåì áóäåò è ìåíüøå âñÿêîãî ðîäà íåêà÷åñòâåííîãî è îòêðîâåííîãî øàðëàòàíñòâà. Ýòî ïîêàçàë è ïîêàçûâàåò îïûò âñåãî ìèðà, íå îáîéäåò îí ñ Áîæüåé ïîìîùüþ è Ðîññèþ. |
#24
|
||||
|
||||
Öèòàòà:
ß íåñêîëüêî ðàç ïðåäëàãàë Âàì îòîéòè îò îáùèõ äåìàãîãè÷åñêèõ ðàññóæäåíèé, îò ïàôîñà, ñ êîòîðûì îäèíàêîâî óñïåøíî ìîæíî âûñòóïàòü çà Ñîâåòñêóþ âëàñòü è ïðîòèâ íå¸, ê êîíêðåòíî ïîëó÷åííûì ðåçóëüòàòàì, ïîêàçàòåëÿì. Íàïðèìåð, ñîâñåì íåäàâíî ÿ äâàæäû ïîäðÿä ïðåäëàãàë Âàì Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#25
|
||||
|
||||
Óâàæàåìûé Âëàäèìèð ßêîâëåâè÷,
À äåéñòâèòåëüíî, êàêèì Bû ñåáå ïðåäñòàâëÿåòå äèçàéí èññëåäîâàíèÿ è ïðåäïîëàãàåìóþ íîçîëîãèþ äëÿ èññëåäîâàíèÿ ìàñëà "Îçîíèä" â óðîëîãè÷åñêîé êëèíèêå? Áîëüøîå ñïàñèáî çà îòâåò. |
#26
|
|||
|
|||
Öèòàòà:
|
#27
|
|||
|
|||
Àëåêñåé Âèêòîðîâè÷!
×òî êàñàåòñÿ ñåïñèñà è îçîíîòåðàïèè, ïîëàãàþ, äîñòàòî÷íî óáåäèòåëüíû ðåçóëüòàòû, íåìåöêèõ èññëåäîâàòåëåé íåñêîëüêèõ èí-òîâ óíèâåðñèòåòà Ìàðáóðãà, Ãåðìàíèÿ, êîòîðûå, ñ Âàøèõ ñëîâ, è ïðåñòàâëåíèÿ îá îçîíîòåðàïèè íå èìåþò. Êðûñû ñàìöû ëèíèè Wistar ïðèìåðíî îäíîãî âåñà (180 - 200 ã), íàóãàä ðàñïðåäåëÿëèñü íà íåñêîëüêî ãðóïï. Âíóòðèáðþøèííîé èíúåêöèåé çàðàæåííîãî ôåêàëüíîãî ìàòåðèàëà ìîäåëèðîâàëñÿ ïåðèòîíèò. Çàòåì íåêîòîðûå ãðóïïû îáðàáàòûâàëèñü ðàçëè÷íûìè àíòèáèîòèêàìè (öåôàëîñïîðèíàìè III–IV ïîêîëåíèÿ, ëåâîôëîêñàöèí, ïèïåðàöèëëèí + òàçîáàêòàì). Äðóãèå òåìå æå ñàìûìè àíòèáèîòèêàìè + ñèñòåìíàÿ îçîíîòåðàïèÿ (ïàðåíòåðàëüíûé îçîí â íèçêèõ äîçèðîâêàõ). Ëåòàëüíîñòü êðûñ â ãðóïïàõ, ãäå èñïîëüçîâàëèñü ëèøü àíòèáèîòèêè, â çàâèñèìîñòè îò ÷óâñòâèòåëüíîñòè ê íèì èñïîëüçóåìîãî â ìîäåëè øòàììà è íà÷àëà ëå÷åíèÿ ïîñëå çàðàæåíèÿ, êîëåáàëàñü îò 80 äî 100 %.  òîæå âðåìÿ â ãðóïïàõ, ãäå âìåñòå ñ àíòèáèîòèêàìè èñïîëüçîâàëàñü îçîíîòåðàïèÿ óæå âûæèâàåìîñòü êðûñ êîëåáàëàñü îò 60 äî 100%. Ê ïðèìåðó, ïðè èñïîëüçîâàíèè Piperacillin/Tazobactam âìåñòå ñ ÎÒ âûæèâàåìîñòü, â çàâèñèìîñòè îò íà÷àëà ëå÷åíèÿ ïîñëå çàðàæåíèÿ áûëà 100 è 78 %, à â ãðóïïàõ, ãäå ýòîò àíòèáèîòèê èñïîëüçîâàëñÿ áåç îçîíà – 0% ! Ýòè äàííûå ÿ ïðèâîäèë íà ôîðóìå íåñêîëüêî ðàç. È êàêàÿ áûëà ðåàêöèÿ?  ëó÷øåì ñëó÷àå: íó, è ëå÷èòå ñâîèì îçîíîì êðûñ. P.S. Àëåêñåé Âèêòîðîâè÷. ß áû ìîã ñîäåéñòâîâàòü îáñóæäåíèþ òåðàïèè öåëûì ðÿäîì âðà÷åé, å¸ èñïîëüçóþùèõ, â òîì ÷èñëå, è çàðóáåæíûõ. Íî îáñòàíîâêà íåòåðïèìîñòè â äèñêóññèîííîì êëóáå, ê ëþáîìó ìíåíèþ, íåñîâïàäàþùåìó ñ ìíåíèåì ìåñòíûõ àâòîðèòåòîâ. Íàñàæäåíèå åäèíîìûñëèÿ ( êàê ó Êîçüìû Ïðóòêîâà "Ïðîåêò: î ââåäåíèÿ åäèíîìûñëèÿ â Ðîññèè") - ýòî îòâåðãàåò â êîðíå. Äà è ó ìåíÿ óæå äàâíî íå âûçûâàåò áîëüøîãî óäîâîëüñòâèÿ ó÷àñòèå íà ýòîì ôîðóìå, áîëüøå ïî îáÿçàííîñòè.  ïåðâûå ãîäû, ÄÊ áûë çíà÷èòåëüíî áîëåå äåìîêðàòè÷íûé. Îäíî «ðàçâëå÷åíèå» íåêîòîðûõ ó÷àñòíèêîâ, êèäàòü ïðè ëþáîì óäîáíîì ñëó÷àå îïïîíåíòàì ÷åðíûå øàðû, ÷åãî ñòîèò! Ê ïðèìåðó, îäíî èç ïîñëåäíèõ ã-íó Çàéöåâó â íàøåé ñ Âàìè äèñêóññèè http://forums.rusmedserv.com/showpos...7&postcount=95 Âû ìîæåòå ïîÿñíèòü, ÷òî â íåì òàêîãî êðèìèíàëüíîãî? |
#28
|
|||
|
|||
Öèòàòà:
Conclusion 1:Ozone pretreatment might prevent lethal peritonitis by controlling inflammatory process generated physiologically into the body against specific damage or specific organism. Conclusions 2:Ozone pre-treatment was pro-inflammatory in sepsis with a trend to reduced survival. Therefore, its effects in sepsis should be further evaluated in animal trials. Êàê áûòü îïïîíåíòàì? Êîìó âåðèòü? Ìîæåò ïðîâåðèì, íó õîòÿ áû åùå ðàçî÷åê, íó ïîæàëóéñòà, ïåðåä äåòñêèì òî îòäåëåíèåì... Inflamm Res. 2004 Aug;53 Suppl 2:S122-5. Epub 2004 Aug 10. Related Articles, Links Pre-treatment with ozonized oxygen (O(3)) aggravates inflammation in septic rats. Torossian A, Ruehlmann S, Eberhart L, Middeke M, Wulf H, Bauhofer A. Department of Anaesthesia and Critical Care, University of Marburg, Baldingerstrasse 1, 35033, Marburg, Germany, [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]. Objective and design:Ozone is produced by neutrophils during bacterial killing. Its application was found to be beneficial in peritonitis patients. Therefore, we measured survival and cytokines after ozone pre-treatment in septic rats. Subjects and treatment:With approval, 40 male Wistar-rats were allocated to 1) ozone pre-treatment for five days before intra-abdominal sepsis, or 2) no pre-treatment. Methods:The primary endpoint was mortality at 120 h. Secondary endpoints were plasma cytokine levels. Results:In the control group mortality was 50% (10/20 rats). After ozone pre-treatment, survival was only 35% (7/20 rats, Log-Rank test: P = 0.10). Ozone increased TNF-alpha and MIP-2 after infection: 127+/-23 pg/ml and 94+/-19 pg/ml (control group: 398 pg/ml and 369 pg/ml; P < 0.002 and P < 0.01). IL-6 levels were similar in both groups. Conclusions:Ozone pre-treatment was pro-inflammatory in sepsis with a trend to reduced survival. Therefore, its effects in sepsis should be further evaluated in animal trials. Âàø îòâåò: Ïîêà íå óâèæó ïîëíûé òåêñò ñòàòüè... Âëàäèìèð ßêîâëåâè÷, óâèäåëè ïîëíûé òåêñò? Íåò. Ïîëó÷àéòå ÷åðíûé øàð. Çà íåæåëàíèå äàòü îòâåò ïî ñóùåñòâó, çà î÷åðåäíîé ïîâòîð, çà èñïîëüçîâàíèå íåäîêàçàííîé ìåòîäèêè íà áåðåìåííûõ è äåòÿõ è çà ïóñòóþ òðàòó íàøåãî âðåìåíè. |
#29
|
|||
|
|||
Öèòàòà:
Öèòàòà:
ß óòî÷íèë êàêèå äîçèðîâêè ïðèìåíÿëèñü â öèòèðóåìîé Âàìè ñòàòüå: êàê è îæèäàëîñü, â íåñêîëüêî ðàç ïðåâûøàþùèå òåðàïåâòè÷åñêèå. À íà Âàøå âðåìÿ ÿ íèêîãäà íå ïðåòåíäîâàë. Âû ïî ñîáñòâåííîé èíèöèàòèâå óæå äëèòåëüíîå âðåìÿ, ïîñòîÿííî çàíèìàåòåñü ïîèñêàì êîìïðîìàòà íà îçîíîòåðàïèþ. Êðîìå òîãî, íà ýòîò ðàç, î÷åðåäíóþ äèñêóññèþ íà ýòîì ôîðóìå èíèöèèðîâàë íå ÿ. |
#30
|
|||
|
|||
Öèòàòà:
Óâàæàåìûé Âëàäèìèð ßêîâëåâè÷, Äâå ðàáîòû ïðîâîäèëèñü â îäíîì è òîì æå ãîðîäå - Ìàðáóðãå: îäíà â Phillips-University, a äðóãàÿ â University of Marburg. Ìîãó ïðåäïîëîæèòü, ÷òî âòîðàÿ ãðóïïà ïîîáùàëàñü ñ ïåðâîé, ò.å. äîêòîð À. Bauhofer ñêîðåå âñåãî ïîçâîíèë äîêòîðó M. Bette è ïåðåãîâîðèë î äèçàéíå è àïïàðàòóðå äëÿ áóäóùåãî èññëåäîâàíèÿ. Ìû, êðîìå òîãî, èìååì âîçìîæíîñòü ñðàâíèòü äâå ðàáîòû, ò.ê. â íàó÷íûõ ñòàòüÿõ, â îòëè÷èå îò îçîíîòåðàïåâòè÷åñêèõ îïóñîâ, åñòü ñïåöèàëüíûé ðàçäåë ïîä íàçâàíèåì: "Ìàòåðèàëû è ìåòîäû". Ðàáîòà äð. Áåòòå: 1. Healthy male Wistar ràts (210-215 g) they were kept in rooms with a standardized air conditioning 20-22 C, 50-57% relative humidity, and 12-hour artificial day/night rhythm. 2. "Ozonized oxygen was generated from medical by an ozone processor (Ozonosan, PTN 60 Dr. Hansler GmbH, Iffezheim, Germany) or from an Ozomed machine, manufactured at the Ozone Research Center in Havana, Cuba. Ozone concentrations were monitoried by using an Ozonosan photometer (Dr. Hansler GmbH). The gas mixture (5% volume ozone and 95% medical oxygen) was insufflated with a standardized volume of 80 ml/kg rat by injection (needle size: 21G) into the right abdominal of the rats by daily injection for 5 days. A òåïåðü ðàáîòà äîêòîðà Áàóõîôåðà: 1. We used 40 male Wistar rats, 220-280 g. They were given a standard diet and water ad libitum. 2. "In the Group 1, 80 ml/kg of an ozone/oxygen gas mixture was given as an intraperitoneal injection on 5 consecutive days before surgery. An ozone generator, Ozonosan PNT 60 (Dr. J. Hansler GmbH, Iffezheim, Germany) was used for preparation of the gas mixture. Ïîêà ïðîòîêîëû ïîõîæè, êàê äâå êàïëè âîäû, ò.å. åñëè äîêòîð Áàóõîôåð è íå ïåðåãîâîðèë ñ äîêòîðîì Áåòòå, òî îí ïðî÷èòàë åãî ðàáîòó, ò.ê. öåëüþ ðàáîòû äîêòîðà Áàóõîôåðà áûëî ïîäòâåðæäåíèå ðåçóëüòàòîâ äîêòîðà Áåòòå, î ÷åì îí è ãîâîðèò â ïðåäèñëîâèè ê ñâîåé ñòàòüå. Òåïåðü î äîçàõ: Äîêòîð Áåòòå: " In the surgical model different ozone concentrations (10 ug/ml, Xmean = 0.93 mg ozone /rat; 50 ug/ml, Xmean = 4.2 mg ozone /rat; 100 ug/ml, Xmean = 7.97 mg ozone/rat)". Äîêòîð Áåòòå äàåò ïîëíûå äîçû îçîíà, ïîëó÷åííûå çà 5 ñåàíñîâ. A òåïåðü äîêòîð Áàóõîâåð, êîòîðûé ïîâòîðÿåò ïðîòîêîë Áåòòå (ñ ìèíèìàëüíîé èç òðåõ êîíöåíòðàöèé, òàê êàê îíà ïîêàçàëà ëó÷øèå ðåçóëüòàòû), äàâàÿ 80 ìë ñìåñè (ñîäåðæàùåé îçîíà 10 ug/ml) íà êã âåñà, ïîëó÷àÿ "An ozone/oxygen gas mixture (800 ug/kg)" è äàåò ýòî "on five consecutive days". Òî åñòü òî æå ñàìîå êîëè÷åñòâî îçîíà. Ïîñëå íåóäà÷è ýêñïåðèìåíòà, äîêòîð Áàóõîâåð äåëàåò ïðåäïîëîæåíèå, ÷òî "the chosen dose of ozone, which was recommended by another group (ññûëêà íà ðàáîòó äîêòîðà Áåòòå), "was still too high to exclude negative immunological effects". Òàê ÷òî ÿ íå ìîãó ñ âàìè ñîãëàñèòüñÿ, ÷òî äîêòîð Áàóõîôåð ïðèìåíèë íåâìåíÿåìî áÎëüøóþ êîíöåíòðàöèþ îçîíà è òåì ñàìûì ïîãóáèë êðûñ. Îáà ó÷åíûõ ñîëèäàðíû â îäíîì: òðåáóþòñÿ äàëüíåéøèå ýêñïåðèìåíòû íà æèâîòíûõ. Äîêòîð Áåòòå: "Therefore, more investigationwith this gas mixture are necessary, especially in combination with antibiotics which will lead to a promising new approach in prevention and /or therapy to overcome severe infectious diseases" Äîêòîð Áàóõîâåð: "Although we cannot recommend pre-treatment with ozonized oxigen for patients at risk for peritonitis based on the result of our study, we conclude that further evaluation of ozone as a therapeutic or prophylactic measure including its mode of action is necessary in ANIMAL models, probably with reduced doses." P.S. Èç ðàáîòû äîêòîðà Áàóõîôåðà: "We thanks Dr. S. Schults [laboratory of d-r M. Bette], Institute of Veterenary Medicine for supporting us with the ozone generator" P.S. Èç ðàáîòû äîêòîðà Áåòòå: "Òhis study was supported by Dr. Viebahn-Hansler (Dr. Hansler GmbH, Germany) [ïðîèçâîäèòåëü îçîíîâûõ àïïàðàòîâ è "ãëàâíûé" íåìåöêèé îçîíîòåðàïåâò] + The work was partly performed in the National Scientific Research Center, Havana, the Ozone Research Center (Dr. Hernandez and Dr. Rosales, Cuba) [ îðãàíèçàöèÿ, èìåþùàÿ ïðÿìóþ ìàòåðèàëüíóþ çàèíòåðåñîâàííîñòü â ïðîäàæå îçîíîâûõ àïïàðàòîâ è ìåòîäèêè] |